7 patents
Utility
Methods and Compositions Involving Bucindolol for the Treatment of Atrial Fibrillation
18 May 23
The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the β1 adrenergic receptor gene.
Michael BRISTOW, Christopher DUFTON
Filed: 6 Jan 23
Utility
Methods and compositions involving bucindolol for the treatment of atrial fibrillation
17 Jan 23
The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the β1 adrenergic receptor gene.
Michael Bristow, Christopher Dufton
Filed: 8 Feb 21
Utility
Methods and compositions involving (S)-bucindolol
27 Sep 22
Disclosed is bucindolol substantially free of its R-stereoisomer.
Michael R. Bristow, Jonathan D. Port
Filed: 13 Dec 18
Utility
Methods and Compositions Involving Bucindolol for the Treatment of Atrial Fibrillation
19 Aug 21
The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the β1 adrenergic receptor gene.
Michael Bristow, Christopher Dufton
Filed: 8 Feb 21
Utility
Methods and compositions involving bucindolol for the treatment of atrial fibrillation
23 Feb 21
The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the β1 adrenergic receptor gene.
Michael Bristow, Christopher Dufton
Filed: 5 May 20
Utility
Methods and Compositions Involving Bucindolol for the Treatment of Atrial Fibrillation
26 Aug 20
The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patientswith heart failure, after being determined to be homozygous Arg389 in the β1 adrenergic receptor gene.
Micheal Bristow, Christopher Dufton
Filed: 4 May 20
Utility
Methods and Compositions Involving (S)-bucindolol
27 Nov 19
Disclosed is bucindolol substantially free of its R-stereoisomer.
Michael R. Bristow, Jonathan D. Port
Filed: 12 Dec 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first